Peter M. Clifton

Frome Road
Adelaide, SA 5000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 172 publications

Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.

Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.

Journal: The New England journal of medicine

Published: August 28, 2026

In Memoriam: Dr Paul John Nestel (1929-2006).

In Memoriam: Dr Paul John Nestel (1929-2006).

Journal: Journal of lipid research

Published: August 24, 2026

Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials.

Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials.

Journal: American journal of preventive cardiology

Published: February 16, 2026

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.

Journal: The New England journal of medicine

Published: November 10, 2025

Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial.

Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial.

Journal: Nature medicine

Published: July 02, 2025

Relationship between homocysteine levels and bone quality in healthy adults - A systematic review and meta-analysis.

Relationship between homocysteine levels and bone quality in healthy adults - A systematic review and meta-analysis.

Journal: Clinical nutrition ESPEN

Published: December 17, 2024

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.

Journal: The New England journal of medicine

Published: May 28, 2024

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.

Journal: NEJM evidence

Published: February 06, 2024

Barriers to and Facilitators of Implementing Guidelines for Detecting Familial Hypercholesterolaemia in Australia.

Barriers to and Facilitators of Implementing Guidelines for Detecting Familial Hypercholesterolaemia in Australia.

Journal: Heart, lung & circulation

Published: October 13, 2022

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.

Journal: Nature medicine

Published: September 23, 2022

The Effect of a Peanut-Enriched Weight Loss Diet Compared to a Low-Fat Weight Loss Diet on Body Weight, Blood Pressure, and Glycemic Control: A Randomized Controlled Trial.

The Effect of a Peanut-Enriched Weight Loss Diet Compared to a Low-Fat Weight Loss Diet on Body Weight, Blood Pressure, and Glycemic Control: A Randomized Controlled Trial.

Journal: Nutrients

Published: May 15, 2022

The effect of cognitive behavioral stress management on perceived stress, biological stress markers and weight loss/regain, from a diet-induced weight loss program: A randomized controlled trial.

The effect of cognitive behavioral stress management on perceived stress, biological stress markers and weight loss/regain, from a diet-induced weight loss program: A randomized controlled trial.

Journal: Comprehensive psychoneuroendocrinology

Published: September 21, 2021

Showing 1-12 of 172

Last Updated: 09/26/2026